J.R. Fischer

A German multicenter, randomized phase III trial comparing irinotecan–carboplatin with etoposide–carboplatin as first-line therapy for extensive-disease small-cell lung cancer

Alexander Schmittel, Martin Sebastian, Ludwig Fischer von Weikersthal et al. · Annals of Oncology · 2011 · 106 citations

Randomized phase 2 trial on refinement of early-stage NSCLC adjuvant chemotherapy with cisplatin and pemetrexed versus cisplatin and vinorelbine: the TREAT study

Michael Kreuter, Johan Vansteenkiste, J.R. Fischer et al. · Annals of Oncology · 2012 · 88 citations · Full text

Medicine, Pharmacology, Clinical Trials +8

A randomized phase III trial comparing standard and high-dose pemetrexed as second-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer

M.H. Cullen, Petr Zatloukal, S Sörenson et al. · Annals of Oncology · 2008 · 73 citations

Second-line Treatment, Medicine, Metronomic Therapy +10

OA04.02 CheckMate 817: First-Line Nivolumab + Ipilimumab in Patients with ECOG PS 2 and Other Special Populations with Advanced NSCLC

Fabrice Barlési, Clarisse Audigier-Valette, Enriqueta Felip et al. · Journal of Thoracic Oncology · 2019 · 48 citations · Full text

Advanced Nsclc, Ecog Ps 2, Therapeutic Efficacy +4

Innovations: Randomized phase II trial of erlotinib (E)/bevacizumab (B) compared with cisplatin (P)/gemcitabine (G) plus B in first-line treatment of advanced nonsquamous (NS) non-small cell lung cancer (NSCLC).

M. Thomas, J.R. Fischer, Stefan Andreas et al. · Journal of Clinical Oncology · 2011 · 20 citations

Oncology, Phase Ii Trial, Pfs 6.2 +13